Potential Effects on Elderly People From Nirsevimab Use in Infants
Nirsevimab therapy has the potential to revolutionize infant respiratory syncytial virus (RSV) prophylaxis. But other populations suffering RSV, such the elderly or those over 60, may also be protected by using this novel antibody in the infant group. It is true that some studies link the use of nir...
שמור ב:
| Principais autores: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2024-04-01
|
| סדרה: | Open Respiratory Archives |
| נושאים: | |
| גישה מקוונת: | http://www.sciencedirect.com/science/article/pii/S2659663624000237 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|